Biopharmaceutical News and Research

RSS

Phase I clinical study evaluates safety and pharmacokinetics of ExeVir's COVID-19 neutralizing antibody

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first subjects have been dosed in a Phase I clinical study of XVR011, its llama-derived antibody for the treatment and prevention of COVID-19.

19 Aug 2021

Atlas Antibodies acquires evitria

Atlas Antibodies has agreed to acquire evitria, a world leader in transient recombinant antibody expression in CHO cells. This transformative acquisition brings together a leading provider of highly validated research antibodies and a front-runner in the field of custom recombinant antibody expression.

From Atlas Antibodies 28 Jul 2021

PerkinElmer to Acquire Antibody and Reagent Leader BioLegend

PerkinElmer, Inc. today announced it has entered into an agreement to acquire BioLegend, a leading, global provider of life science antibodies and reagents.

From Revvity 27 Jul 2021

Llama ‘nanobodies’ have the potential to outwit human cytomegalovirus

Scientists have developed a 'nanobody' - a small fragment of a llama antibody - that is capable of chasing out human cytomegalovirus (HCMV) as it hides away from the immune system.

22 Jul 2021

Research reveals clues to how a molecule improves appearance of surgery scars

Surgical scars treated with a molecule called alphaCT1 showed a long-term improvement in appearance when compared to control scars, according to multicenter, controlled Phase II clinical trials - a finding that could help surgeons improve patient outcomes.

20 Jul 2021

Redhill Biopharma announces completion of Phase 2/3 COVID-19 study of oral opaganib

RedHill Biopharma Ltd., a specialty pharma company that is a leader in the development of novel oral therapies for COVID-19, today announced that all treatment and follow-up has now been completed in the 475-patient global Phase 2/3 study with opaganib (ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840). Top-line results are expected in the coming weeks.

20 Jul 2021

Curia to Acquire US-based LakePharma, Expanding End-to-End R&D Capabilities and Scale for Biologics

Curia today announced it has entered into a definitive agreement to acquire LakePharma Inc.

From Curia 14 Jul 2021

Curia to Acquire Integrity Bio, Expanding Biologic Formulation and Fill-Finish Capabilities

Curia today announced it has entered into a definitive agreement to acquire Integrity Bio, Inc., a privately held formulation and fill-finish organization.

From Curia 13 Jul 2021

Nikalyte Announces New Partnership with Life Science Group Calibre Scientific

Nanoparticle deposition specialists, Nikalyte Ltd announced that the company has signed a partnership agreement with global life sciences group Calibre Scientific.

From Nikalyte Ltd 8 Jul 2021

WEHI collaborates with Boehringer Ingelheim to develop novel anti-cancer therapeutics

WEHI has partnered with Boehringer Ingelheim, a leading research-driven pharmaceutical company, in a collaboration to discover and develop anti-cancer therapeutics using a promising new technology called targeted protein degradation.

25 Jun 2021

Repligen Corporation Announces Agreement to Acquire Polymem S.A.

Repligen Corporation today announced that it has entered into an agreement to acquire Toulouse, France-based Polymem S.A., a leading industrial expert.

23 Jun 2021

Insilico Medicine receives $255 million to develop AI and drug discovery capabilities

Insilico Medicine, a global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, announced that it has closed a $255 million from biotechnology experts to progress Insilico Medicine's current therapeutic programs into human clinical trials, initiate multiple new programs for novel and difficult targets, and further develop its AI and drug discovery capabilities.

23 Jun 2021

Study determines the mechanism behind respiratory inflammation and finds effective treatment

Applied Biological Laboratories (Applied Bio), a biopharmaceutical company focused on the respiratory disease market, announced that its study published online in Immunology, Inflammation and Disease was able to determine the mechanism behind respiratory inflammation and treat it effectively with Biovanta(TM), a 100% naturally derived, over-the-counter (OTC) drug for cold, cough and sore throat.

22 Jun 2021

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced presentation of the positive Phase 2 safety and efficacy data for oral opaganib (Yeliva®, ABC294640) in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum (WMF) 2021 (poster #: 5574).

21 Jun 2021

KIYATEC’s test results accurately predict treatment response in recurrent high-grade glioma patients

KIYATEC, Inc. announced today the publication of new peer-reviewed data that establishes clinically meaningful prediction of patient-specific responses to standard of care therapy, prior to treatment, in newly diagnosed glioblastoma (GBM) and other high-grade glioma (HGG) patients.

18 Jun 2021

Foresight Diagnostics to demonstrate utility of PhasED-Seq technology at ICML meeting

Foresight Diagnostics, the emerging leader in blood-based lymphoma disease monitoring, announced today that clinical performance of its minimal residual disease (MRD) detection platform in diffuse large B-cell lymphoma (DLBCL) will be presented at the 16th International Conference on Malignant Lymphoma (ICML) on June 18-22, 2021.

18 Jun 2021

Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001

Enterprise Therapeutics Ltd today announced it has successfully dosed the first subjects in a Phase 1 trial for its novel inhaled cystic fibrosis therapy, ETD001.

14 Jun 2021

PhoreMost appoints Christian Dillon as Vice President of Biology

PhoreMost Ltd today announced it has appointed Dr Christian Dillon as Vice President of Biology.

From PhoreMost 14 Jun 2021

Autobahn Labs collaborates with CSHL to advance science from the lab to clinic

Autobahn Labs, an early-stage drug discovery incubator, today announced a new strategic venture collaboration with Cold Spring Harbor Laboratory.

7 Jun 2021

Redhill Biopharma announces completion of enrollment for oral opaganib phase 2/3 COVID-19 study

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has completed enrollment and randomized the last patient in the global Phase 2/3 study with opaganib (Yeliva, ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840).